Caladrius Biosciences, Inc. (formerly NeoStem) is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s subsidiary, PCT, is a development and manufacturing partner exclusively focused on the cell therapy industry. PCT provides a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage, and distribution, as well as expert consulting and regulatory support.
Type | Public | |
Founded | 2006 | |
HQ | New York, NY, US | Map |
Website | caladrius.com | |
Employee Ratings | More |
USD | |
---|---|
Net income (Q3, 2020) | (5.3m) |
EBIT (Q3, 2020) | (5.3m) |
Market capitalization (15-Jan-2021) | 30.5m |
Closing stock price (15-Jan-2021) | 1.6 |
Cash (30-Sept-2020) | 21.2m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 18.5m | 17.8m | 22.1m | 3.4m | 4.4m | 2.5m | 4.4m | 3.7m | 4.1m | 4.5m | 4.1m | 3.2m | 5.9m | 5.9m | 7.5m | 8.3m | 9.3m | 7.9m | |||||||||||
Cost of goods sold | 13.5m | 13.8m | 16.3m | 2.7m | 3.7m | 2.4m | 4.2m | 3.0m | 3.8m | 3.7m | 4.0m | 3.4m | 5.8m | 4.8m | 6.2m | 7.1m | 8.6m | 8.0m | |||||||||||
Gross profit | 4.9m | 3.9m | 5.7m | 636.1k | 686.5k | 131.8k | 124.4k | 731.0k | 230.1k | 811.6k | 105.4k | (196.3k) | 68.2k | 1.1m | 1.3m | 1.2m | 706.3k | (119.6k) | |||||||||||
Gross profit Margin, % | 27% | 22% | 26% | 19% | 15% | 5% | 3% | 20% | 6% | 18% | 3% | (6%) | 1% | 18% | 17% | 15% | 8% | (2%) |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 4.9m | 11.7m | 21.8m | 2.1m | 5.4m | 9.3m | 14.7m | 16.9m | 41.4m | 32.9m | 32.1m | 19.1m | 36.2m | 24.0m | 25.4m | 17.7m | 18.6m | 12.0m | 23.0m | 15.1m | 21.6m | 22.7m | 14.4m | 14.4m | 11.8m | 12.7m | 20.7m | 26.7m | 21.2m |
Accounts Receivable | 7.4m | 8.9m | 10.4m | 1.3m | 1.8m | 886.2k | 701.6k | 1.4m | 1.9m | 2.5m | 2.1m | 2.0m | 1.3m | 2.3m | 3.2m | 335.6k | 401.6k | 144.3k | |||||||||||
Prepaid Expenses | 1.3m | 1.8m | 2.2m | 882.8k | 3.2m | 995.1k | 993.3k | 1.5m | 1.8m | 2.5m | 4.4m | 4.3m | 4.0m | 3.4m | 3.2m | 5.7m | 920.0k | 793.0k | 1.2m | 1.1m | 1.3m | 1.2m | 1.1m | 461.0k | 1.7m | 989.0k | |||
Inventories | 25.0m | 20.6m | 18.0m | 1.2m | 448.0k | 1.5m | 32.0k | 529.4k | 1.5m | 2.0m | 2.1m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (47.1m) | (53.8m) | (39.5m) | (55.5m) | (81.0m) | (33.3m) | 22.2m | (16.2m) | (19.4m) |
Depreciation and Amortization | 9.0m | 1.6m | 1.6m | 2.2m | 2.7m | 2.7m | 372.0k | 225.0k | 65.0k |
Inventories | 4.6m | (465.3k) | (157.2k) | (1.3m) | (344.8k) | (670.6k) | |||
Cash From Operating Activities | (20.9m) | (13.9m) | (27.1m) | (46.9m) | (39.3m) | (23.7m) | (20.9m) | (20.0m) | (18.9m) |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (20.8m) | (28.3m) | (9.3m) | (29.9m) | (38.3m) | (8.8m) | (17.4m) | (26.8m) | (13.8m) | (26.6m) | (43.8m) | (19.2m) | (36.4m) | (47.8m) | (12.0m) | (19.9m) | (27.2m) | (9.8m) | 28.7m | 25.1m | (5.0m) | (9.1m) | (12.6m) | (4.4m) | (9.5m) | (14.4m) | (4.0m) | 2.6m | (2.7m) |
Depreciation and Amortization | 4.6m | 6.8m | 2.2m | 774.8k | 1.2m | 555.0k | 832.9k | 1.2m | 444.5k | 987.7k | 1.6m | 604.4k | 1.3m | 1.9m | 737.2k | 1.4m | 2.1m | 655.3k | 193.8k | 284.0k | 87.3k | 169.4k | 208.0k | 17.0k | 35.0k | 50.0k | 15.0k | 30.0k | 46.0k |
Inventories | (1.5m) | 3.1m | (726.3k) | (513.6k) | 199.7k | (428.5k) | 1.1m | 583.7k | (205.6k) | (762.8k) | (872.1k) | (1.1m) | (406.5k) | (781.6k) | 43.7k | ||||||||||||||
Cash From Operating Activities | (13.3m) | (17.5m) | 2.1m | (852.3k) | (4.2m) | (7.1m) | (13.1m) | (19.7m) | (11.3m) | (22.5m) | (36.0m) | (14.2m) | (21.8m) | (30.5m) | (8.0m) | (14.6m) | (20.3m) | (10.1m) | (15.6m) | (16.9m) | (6.3m) | (12.2m) | (16.9m) | (5.5m) | (10.2m) | (14.7m) | (4.2m) | 262.0k | (3.3m) |
USD | Q2, 2011 |
---|---|
Financial Leverage | 1.9 x |
Caladrius has 1.55k Twitter Followers. The number of followers has decreased 0.7% month over month and decreased 0.5% quarter over quarter
526
Tweets
290
Following
1.6k
Followers
3
Tweets last 30 days
0.7
Avg. likes per Tweet
100%
Tweets with engagement
When was Caladrius founded?
Caladrius was founded in 2006.
Who are Caladrius key executives?
Caladrius's key executives are David J. Mazzo, Gregory B. Brown and Robert Honigberg.
How many employees does Caladrius have?
Caladrius has 27 employees.
Who are Caladrius competitors?
Competitors of Caladrius include Beacon Clinical Research, BlackThorn Therapeutics and Sophiris.
Where is Caladrius headquarters?
Caladrius headquarters is located at 420 Lexington Ave # 350, New York.
Where are Caladrius offices?
Caladrius has offices in New York and Rye Brook.
How many offices does Caladrius have?
Caladrius has 2 offices.
Receive alerts for 300+ data fields across thousands of companies